THE ANABOLICPROTOCOL
MedicationsLow risk

Telmisartan

Also known as: Micardis

Angiotensin-receptor blocker used on cycle to keep blood pressure in check — favored for its long duration and studied metabolic side benefits.

Substance family

Cardiovascular & metabolic agents

Medications for blood pressure, lipids and glucose. They appear here because these are exactly the markers most anabolic compounds push in the wrong direction.

Effects on

Which outcomes this substance acts on — descriptive, not a recommendation.

Strain profile

Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.

Liver
minimal
Kidneys
low
Blood lipids
minimal
Hematocrit
minimal
Blood pressure
minimal
Hormonal axis
minimal

This substance works against

Dosing & protocols by goal

Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.

Blood-pressure control (on cycle)

Ancillary

Dose

20–80 mg / day

Frequency

1× / day

Cycle length

While blood pressure is elevated

Start low, titrate to actual blood-pressure readings; long half-life gives smooth 24 h coverage.

Supraphysiological doses carry significant health risks and are not legal without a medical indication. This information serves education and harm reduction, not as a usage recommendation. Accompanying blood work and — where relevant — a post-cycle plan (PCT) are essential. See the disclaimer.

Overview

Telmisartan is an angiotensin-receptor blocker (ARB) — a well-tolerated blood-pressure medication. In the enhancement context it is used because many anabolic substances raise blood pressure (via water retention, higher hematocrit and vascular effects), and telmisartan's long duration makes it convenient.

Mechanism of Action

It blocks the angiotensin-II receptor, relaxing blood vessels and lowering blood pressure. Telmisartan is also studied for mild PPAR-gamma activity, which has drawn interest for metabolic side effects — though blood-pressure control is the primary use here.

Typical Context

Used on cycle when blood pressure trends high, alongside cardio and sensible water/sodium management. It is a genuine antihypertensive, not a supplement, and belongs under medical supervision.

Side Effects & Risks

  • Dizziness, especially when starting or when blood pressure is already lower
  • Elevated potassium in some people
  • Caution with kidney impairment and certain drug combinations

Blood Work & Monitoring

  • Blood pressure — the primary metric to titrate against
  • Kidney function (eGFR, potassium) — before and during use
  • General panel during longer use

Harm-Reduction Notes

  • Actually measure blood pressure (home cuff) rather than guessing
  • Cardio and controlling water/hematocrit address the root cause; medication is an adjunct
  • Coordinate with a physician, especially if combining with other blood-pressure drugs

Legal status by region

Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.

RegionRegulatory status
United StatesPrescription-only medicineApproved for defined indications; use outside them is off-label.
EU / UKPrescription-only medicineApproved for defined indications.
Canada / AustraliaPrescription-only medicine
Parts of Asia, Latin America & Middle EastPharmacy availability variesSeveral countries dispense it without prescription in practice. Rules and enforcement differ and change.
Competitive sportCheck the current WADA listSome substances in this class are prohibited, others are not.
All content on this page is for information and harm-reduction purposes only. It is not medical advice, not a recommendation to purchase or use, and does not replace consulting a doctor. Legal status and enforcement vary by country and change; verifying the current rules in your own jurisdiction is your responsibility. For adults 18+ only. See the full disclaimer.